Physician profile
Ranjit Nair
NPI 1598045700
$22,602.11
in general payments reported to CMS, 2019-2025
21 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2020: $105 · 2021: $55.20 · 2022: $946 · 2023: $5,185 · 2024: $15K · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $3,565 · Food and Beverage: $1,318 · Education: $73.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,525.00 |
| Travel and Lodging | $3,565.19 |
| Food and Beverage | $1,317.89 |
| Education | $73.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $12,566.88 | 2024 | |
| Abbvie INC. | $3,300.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $2,144.66 | 2024 | |
| Astrazeneca Uk Limited | $1,609.53 | 2023 | |
| Inspire Medical Systems, INC. | $1,117.84 | 2024-2025 | Inspire |
| Intuitive Surgical, INC. | $677.48 | 2022 | |
| Glaxosmithkline, LLC. | $291.47 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astellas Pharma US INC | $172.99 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $150.00 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $135.29 | 2022-2025 | |
| Kyowa Kirin, INC. | $121.73 | 2023 | Poteligeo |
| Abbott Laboratories | $92.05 | 2024 | Mitraclip |
| Gilead Sciences, INC. | $63.47 | 2022 | |
| Seagen INC. | $55.20 | 2021 | |
| Medtronic, INC. | $38.48 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $26.57 | 2025 | Neffy |
| Tactile Systems Technology INC | $20.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.64 | 2025 | Glassia |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.